Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

by Wong, Alexander , Plesniak, Robert , Takaguchi, Koichi , Vata, Andrei , Janssen, Harry L.A. , Pojoga, Cristina , Hou, Jinlin , Stepanova, Tatyana , Janczewska, Ewa , Popescu, Corneliu P. , Plein, Helene , Diaconescu, Gheorghe , Lukić, Tamara , Campbell, Fiona , Idriz, Nevin , Arbune, Manuela , Cremer, Jennifer , Paff, Melanie , Gadano, Adrian , Tsuji, Keiji , Andreone, Pietro , Maynard, Lauren , Rizzardini, Giuliano , Imamura, Michio , Theodore, Dickens , Yim, Hyung Joon , Quinn, Geoff , Elston, Robert , Lim, Seng-Gee , Asselah, Tarik , Yuen, Man-Fung , Park, Sung Jae , Kendrick, Stuart , Heo, Jeong

in Alanine transaminase / Antigens / Antisense oligonucleotides / Antiviral Agents - adverse effects / Antiviral Agents - therapeutic use / Antiviral drugs / Chronic infection / DNA, Viral - blood / Fever / Gastroenterology / Gastroenterology General / Genetics / Hepatitis / Hepatitis B / Hepatitis B e Antigens - blood / Hepatitis B surface antigen / Hepatitis B Surface Antigens - blood / Hepatitis B virus - genetics / Hepatitis B, Chronic - drug therapy / Hepatitis B, Chronic - virology / Humans / Hypothesis testing / Infections / Infectious Disease / Injections, Subcutaneous / International organizations / Laboratories / Liver cancer / Liver Disease / Liver diseases / Nucleoside analogs / Nucleotide analogs / Oligonucleotides, Antisense - administration & dosage / Oligonucleotides, Antisense - adverse effects / Oligonucleotides, Antisense - therapeutic use / Placebos / Response rates / RNA Therapeutics / RNA, Messenger - drug effects / RNA, Viral - drug effects / Treatment Outcome / Viral Infections

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

2022

Confirm

Do you wish to request the book?

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

Wong, Alexander,

Plesniak, Robert,

Takaguchi, Koichi,

Vata, Andrei,

Janssen, Harry L.A.,

Pojoga, Cristina,

Hou, Jinlin,

Stepanova, Tatyana,

Janczewska, Ewa,

Popescu, Corneliu P.,

Plein, Helene,

Diaconescu, Gheorghe,

Lukić, Tamara,

Campbell, Fiona,

Idriz, Nevin,

Arbune, Manuela,

Cremer, Jennifer,

Paff, Melanie,

Gadano, Adrian,

Tsuji, Keiji,

Andreone, Pietro,

Maynard, Lauren,

Rizzardini, Giuliano,

Imamura, Michio,

Theodore, Dickens,

Yim, Hyung Joon,

Quinn, Geoff,

Elston, Robert,

Lim, Seng-Gee,

Asselah, Tarik,

Yuen, Man-Fung,

Park, Sung Jae,

Kendrick, Stuart,

Heo, Jeong

2022

Overview

In a phase 2 trial, bepirovirsen, an antisense oligonucleotide that targets all hepatitis B virus mRNAs, resulted in sustained loss of hepatitis B surface antigen and HBV DNA in 9 to 10% of participants with chronic HBV infection.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Alanine transaminase

/ Antigens

/ Antisense oligonucleotides

/ Antiviral Agents - adverse effects

/ Antiviral Agents - therapeutic use

/ Antiviral drugs

/ Chronic infection